RE:RE:RE:The restart has started!This is what part 4 states:
Part 4 (basket expansion): selected cancer type diagnosed with histologically or
cytologically confirmed cancers, where TH1902 has been studied and/or showed activity (in
Parts 1 to 3), that is refractory or resistant to standard therapies, and where current
therapy is not considered to be providing benefit.
Note that no specific cancer is mentioned, just "selected cancer". Because when this was written (Feb 24, 2023) they still didn't know.
If the trial really has restarted then THTX needs to do a press release. No more communication through "hints", or us trying to do investigative work. That is not how public companies should operate.